Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011

Vaccine

Volumn 34, Issue 1, 2016, Pages 167-171

  Naleway, Allison L ^a   Crane, Brad ^a   Smith, Ning ^a   Daley, Matthew F ^b   Donahue, James ^c   Gee, Julianne ^d   Greene, Sharon K ^e   Harrington, Theresa ^d   Jackson, Lisa A ^f   Klein, Nicola P ^g   Tseng, Hung Fu ^b   Vellozzi, Claudia ^d   Weintraub, Eric S ^d  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b KAISER PERMANENTE   (United States)

^c MARSHFIELD CLINIC   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f GROUP HEALTH RESEARCH INSTITUTE   (United States)

^g DIVISION OF RESEARCH   (United States)

Author keywords

Adolescents; Human papillomavirus vaccine; Safety; Venous thromboembolism

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERCOAGULABILITY; INCIDENCE; INJURY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OBESITY; ONSET AGE; ORAL CONTRACEPTIVE USE; PAPILLOMAVIRUS INFECTION; PATIENT HISTORY OF SURGERY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; VACCINATION; VENOUS THROMBOEMBOLISM; YOUNG ADULT; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY;

ADOLESCENT; ADULT; CHILD; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84949684492     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.006     Document Type: Article

References (19)

1. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302:750-757.
2. Gee J., Naleway A., Shui I., Baggs J., Yin R., Li R., et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011, 29:8279-8284.
3. Klein N.P., Hansen J., Chao C., Velicer C., Emery M., Slezak J., et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012, 166:1140-1148.
4. Arnheim-Dahlstrom L., Pasternak B., Svanstrom H., Sparen P., Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunization of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. Br Med J 2013, 347:f5906.
5. Harris S.T., Williams D.M., Fediurek J., Scott T., Deeks S.L. Adverse events following immunization in Ontario's female school-based HPV program. Vaccine 2014, 32:1061-1066.
6. Scheller N.M., Pasternak B., Svanstrom H., Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA 2014, 312:187-188.
7. Food and Drug Administration. October 16 2009 Approval Letter - Gardasil. Available at: [accessed 18.02.15]. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186991.htm.
8. Baggs J., Gee J., Lewis E., Fowler F., Benson P., Lieu T., et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011, 127(Suppl. 1):S45-S53.
9. Whitaker H.J., Hocine M.N., Farrington C.P. The methodology of self-controlled case series studies. Stat Methods Med Res 2009, 18:7-26.
10. Spencer F.A., Emery C., Lessard D., Anderson F., Emani S., Aragam J., et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006, 21:722-727.
11. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton J.L. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 1998, 158:585-593.
12. Fowkes F.J., Price J.F., Fowkes F.G. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 2003, 25:1-5.
13. Heinemann L.A., Dinger J.C. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007, 75:328-336.
14. Ageno W., Squizzato A., Garcia D., Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006, 32:651-658.
15. Boulet S.L., Grosse S.D., Thornburg C.D., Yusuf H., Tsai J., Hooper W.C. Trends in venous thromboembolism-related hospitalizations, 1994-2009. Pediatrics 2012, 130:e812-e820.
16. Naleway A.L., Gold R., Kurosky S., Riedlinger K., Henninger M.L., Nordin J.D., et al. Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. Vaccine 2013, 31:2898-2903.
17. White R.H., Garcia M., Sadeghi B., Tancredi D.J., Zrelak P., Cuny J., et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 2010, 126:61-67.
18. Yih WH, Greene SK, Zichittella L, deJong JL, Gil-Prieto R, Griffin MR, et al. Mini-sentinel medical product assessment: evaluation of the risk of venous thromboembolism after gardasil vaccination. Available at: [accessed April 29.04.15]. http://www.mini-sentinel.org/assessments/medical_events/default.aspx.
19. IOM (Institute of Medicine) Adverse effects of vaccines: evidence and causality 2012, National Academies Press, Washington, DC.